Trial Profile
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores greater than or equal to 25
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide
- Indications Early breast cancer
- Focus Therapeutic Use
- 05 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov record
- 05 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 30 Apr 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.